Colorado Cannabis Company: Q1 Revenue Skyrockets 293% YoY To $1.1M Amid German Market Focus, Eyeing European Expansion

Zinger Key Points
  • CBD of Denver reports a dramatic 293% year-over-year revenue increase, driven by Luxora's wholesale division.
  • The company achieved $418,000 in April revenue, the highest month of 2024, amid anticipation of German cannabis regulation changes.
  • Strategic European market focus positions CBD of Denver for further growth in medical cannabis applications and technological innovations.

CBD of Denver Inc. CBDD released its financial results Friday for the first quarter of 2024, showing a significant increase in revenue to $1.1 million, up from $285,779 in the same period last year. The Colorado-based cannabis company’s startling 293% year-over-year revenue growth is primarily driven by enhanced sales volume from Luxora’s wholesale division.

The company’s effective collaboration between its Swiss accounting partners and U.S.-based legal counsel has also been crucial in maintaining operational efficiency and compliance with regulatory frameworks.

Q1 2024 Financial Highlights

  • Revenue was $1.1 million, a significant rise from $285,779 in the same period last year.
  • Net loss was $96,657, compared to the $62,844 from Q1 2023.
  • Adjusted EBITDA was not included in the earnings report.
  • Gross profit was $147,377, a notable increase compared to the $36,300 in the same quarter last year.

Stay ahead in the cannabis industry by joining industry leaders and experts at the upcoming Benzinga Cannabis Capital Conference in Chicago on Oct. 8-9. Get your tickets now before prices surge by following this link.

Record Revenues Amid Legislative Anticipation

Despite global market uncertainties, CBD of Denver's strategic initiatives have yielded robust April revenues of approximately $418,000, marking it as the most successful month of the year. The company attributes this success to its continued focus on the European market, particularly in anticipation of legislative changes in Germany. A pivotal debate on Germany’s cannabis regulation is scheduled for May 16, 2024, which could further influence the company's operations.

CBD of Denver remains focused on exploring new opportunities in the European cannabis sector. Efforts include advancing medical cannabis applications, technological innovations, and other auxiliary services to expand its market presence.

CBDD Price Action
CBDD's shares were trading 10% higher at $0.0011 per share at the time of this writing around 10:45 AM ET Friday.

Related News

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: CannabisEarningsNewsCannabis EarningsCBDColorado CannabisGermany CannabisLuxora
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!